The National Health Service (NHS) has announced a significant expansion of its childhood immunisation programme, the largest in a decade, with the introduction of a routine chickenpox vaccine for all babies starting next year. This move is anticipated to transform chickenpox from a common childhood ailment into a preventable disease, potentially saving lives and reducing the societal burden associated with the illness.

Historically, contracting chickenpox was often viewed as an unavoidable childhood experience. However, despite its often mild presentation, chickenpox, caused by the varicella-zoster virus, can lead to severe complications such as pneumonia, brain inflammation (encephalitis), and serious bacterial infections. In rare instances, these complications can be fatal, with an average of 25 deaths annually in England and hundreds of babies requiring hospitalisation due to severe symptoms. The disease is also particularly dangerous during pregnancy, posing risks to both mother and baby. Highly contagious, chickenpox is capable of spreading rapidly, with each infected individual potentially transmitting the virus to ten others, making it significantly more contagious than common cold or flu viruses.

Beginning in January, the chickenpox vaccine, also known as the varicella vaccine, will be integrated into a new combined Measles, Mumps, Rubella, and Varicella (MMRV) jab, which will supersede the existing MMR vaccine. This MMRV jab is a live vaccine containing a weakened form of the chickenpox virus. While highly effective, it is not recommended for individuals with compromised immune systems due to conditions like HIV or treatments such as chemotherapy. The vaccine boasts a high efficacy rate, being 98 percent effective. Nine out of ten children develop immunity after a single dose, with this figure increasing further after the second dose. While it significantly reduces the risk of developing chickenpox or experiencing severe cases, it does not guarantee lifelong immunity, as protection can wane over time, especially in vaccinated teenagers and adults. This initiative brings the UK in line with many other developed nations, including Germany, Canada, Australia, and the US, which already offer routine varicella vaccination.

The safety of the chickenpox jab has been repeatedly affirmed by experts. Common side effects are typically mild and short-lived, including a sore arm, a mild rash, and a high temperature, consistent with those of other vaccines. Serious side effects, such as severe allergic reactions, are extremely rare, occurring in approximately one in a million people. The MMRV jab does carry a small risk of seizures, estimated at one additional seizure for every 2,300 doses given. However, the Joint Committee on Vaccination and Immunisation (JCVI) has deemed this